Form 4: Seres Therapeutics Director Granted Stock Options

Seres Therapeutics, Inc. Director Dennis A. Ausiello was granted 6,452 stock options with an exercise price of $10.71, vesting quarterly over one year.

Summary

• Dennis A. Ausiello, a Director of Seres Therapeutics, Inc. (MCRB), was granted 6,452 stock options.
• The options have an exercise price of $10.71 per share.
• The grant date for these options was July 1, 2025.
• The options will vest in four equal quarterly installments on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026.
• The final vesting installment may occur on the day immediately prior to the issuer's 2026 annual meeting of stockholders if it happens before July 1, 2026.
• Vesting is contingent upon the reporting person continuing to serve on the Board as a non-employee director through the applicable vesting date.
• The options expire on July 1, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine stock option grant to a director, which is a positive for aligning interests but does not contain significant new operational or financial news. It's a standard compensation event.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard compensation practice for non-employee directors, reflecting ongoing commitment to the company.

Negatives

• The potential future exercise of these options could lead to minor share dilution, though the amount is relatively small.

Risks

• The value of the stock options is directly tied to the future performance of Seres Therapeutics' common stock, meaning the options may not be 'in the money' if the stock price does not exceed the exercise price.
• Vesting is conditional on continued service as a non-employee director, meaning the options could be forfeited if service ceases before vesting dates.

Future Outlook

The document details a future vesting schedule for stock options granted to a director, aligning their long-term incentives with the company's performance through July 2026 and potentially beyond.

Industry Context

Granting stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and growth-oriented sectors, to attract and retain experienced board members and align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation mechanism widely adopted by publicly traded companies, including those in the biotechnology sector like Seres Therapeutics.
• The specific number of options (6,452) and the exercise price ($10.71) are specific to Seres Therapeutics' compensation philosophy and stock valuation at the time of grant, and would typically be benchmarked against peer companies of similar market capitalization and stage of development.
• The four-quarter vesting schedule is a common approach to ensure continued service and long-term alignment, comparable to similar equity grants seen at companies like Moderna or BioNTech for their non-executive board members, though the specific terms vary.

Related Party Transactions

• The stock option grant to a director is a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. There is a minor potential for future dilution if options are exercised.
• Employees: No direct impact on employees mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders mentioned.

Next Steps

• The stock options will vest in four equal quarterly installments, contingent on the director's continued service.
• The director may choose to exercise the options at any time after vesting and before the expiration date, subject to company policy and insider trading rules.

Key Dates

Recommendation

Keywords

Seres Therapeutics, MCRB, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting, Corporate Governance